Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
28 hedge funds and large institutions have $70M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Corbin Capital Partners
New York
|
+$8.99M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.67M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$5.81M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$5.81M |
| 5 |
ACM
Atalaya Capital Management
New York
|
+$5.39M |
Top Sellers
BIOT Hedge Fund Activity: Q1 2021 in Review
28 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q1 2021, worth a combined $70M.
Buyers outnumbered sellers: 28 funds opened new BIOT positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Corbin Capital Partners, opening a new position worth an estimated $8.99M.
- 28 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $70M of Biotech Acquisition Company Class A Ordinary Shares stock for Q1 2021.
- 28 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q1 2021 and 0 closed out, a net change of +28 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q1 2021 was Corbin Capital Partners, an estimated $8.99M added.
Based on aggregated 13F filings for Q1 2021.